Orphan Drugs & Rare Diseases- Innovative Strategies for Getting Orphan Drugs to Where They Are Needed

-

The call to treat rare diseases has become increasingly greater around the world than ever before. Supportive organisations including patient groups, national health authorities, health trusts, academia, HTAs, pharmaceutical and biotechnical companies are now progressively growing in numbers and sophistication in their approaches to medicinal care for those with rare and ultra-rare diseases.

SMi’s Orphan Drugs & Rare Diseases conference will present briefings from key opinion leaders, those with hands-on experience of regulating new drug discoveries, companies that have already developed advanced orphan drugs & successfully been granted orphan medicine status and selected experts in the field. Our expert speakers will offer unique insights into cutting-edge international developments taking place in: expanding the reach of medicine to previously untreatable and unreachable patients with rare diseases; different regulatory and policy environments; new drug discoveries; innovative business strategies & funding & financing models, and the importance of partnerships with patient groups and those at the point-of-care.

Key benefits of attending:

• Learn about health technology assessment protocols and market access in the EU and globally
• Network with key regulators of orphan medicines and policy makers for national rare disease treatment
• Discover successful funding, financing and economic models for orphan drug development and translational research
• Analyse industry case studies showing how R&D and market access costs can be reduced
• Understand the latest developments in ultra-rare diseases studies and new medicines for them
• Explore how organisations are merging research, resources and expertise in the race to cure rare diseases

Hear keynote addresses from:
• Dr. Edmund Jessop, Medical Advisor, National Commissioning Group for Highly Specialised Services, NHS
• Josie Godfrey, Head of Policy and Coordination, AGNSS

• Stephen Nutt, Executive Officer, Rare Disease UK

• Carlos R. Camozzi, MD, PhD, MBA, Vice President, Chief Medical Officer, uniQure B.V.

• Marisa Jaconi, Vice-Director and Founder, Swiss Institute of Cell Therapies (SICT)

• Samantha Parker, Director of External Affairs and Rare Disease Partnerships, Orphan Europe


Location:
Copthorne Tara Hotel, London
Scarsdale Place,
Kensington,
Kensington & Chelsea,
London,
W8 5SR
UK


Organizer: SMi Group Ltd

8 Oct 2012

UPCOMING FEATURED EVENTS 1 Next 
HPLC 201411 May 2014 Read
Neuroscience 201415 Nov 2014 Read


ALL UPCOMING EVENTS
1 2 3 Next 
Medica 201412 Nov 2014 Read
Neuroscience 201415 Nov 2014 Read
Translating Innovations in Diabetes Drug Development17 Nov 2014 Read
ASCB 20146 Dec 2014 Read

Write a Review

Join the Global SelectScience Community Today! It’s FREE!

Helping you make informed decisions about the latest lab products and technologies:

  • Be the first to learn about new technologies
  • 10,000+ trusted product reviews from your peers
  • Compare 500,000 products and manufacturers
  • Get exclusive buying tips from experts
  • Find solutions fast: 10,000+ Application Notes, Webinars and Videos

Connect with 250,000 scientists... All in one place!

Become a member today!